EDN1 and type 2 diabetes mellitus: A recent double-blind, placebo-controlled trial showed that the endothelin antagonist avosentan significantly reduced albuminuria when added to standard treatment in T2DM patients [27].These studies provide further evidence of the role of ET-1 in the pathogenesis of DKD and of its status as a promising treatment target for this complication.